2ghm: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
[[Image:2ghm.gif|left|200px]] | [[Image:2ghm.gif|left|200px]] | ||
<!-- | |||
The line below this paragraph, containing "STRUCTURE_2ghm", creates the "Structure Box" on the page. | |||
You may change the PDB parameter (which sets the PDB file loaded into the applet) | |||
or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |||
or leave the SCENE parameter empty for the default display. | |||
| | --> | ||
| | {{STRUCTURE_2ghm| PDB=2ghm | SCENE= }} | ||
}} | |||
'''Mutated MAP kinase P38 (Mus Musculus) in complex with Inhbitor PG-895449''' | '''Mutated MAP kinase P38 (Mus Musculus) in complex with Inhbitor PG-895449''' | ||
Line 31: | Line 28: | ||
[[Category: Pokross, M E.]] | [[Category: Pokross, M E.]] | ||
[[Category: Walter, R L.]] | [[Category: Walter, R L.]] | ||
[[Category: | [[Category: Map kinase p38]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 05:07:03 2008'' | |||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on |
Revision as of 05:07, 4 May 2008
Mutated MAP kinase P38 (Mus Musculus) in complex with Inhbitor PG-895449
OverviewOverview
A new class of tumor necrosis factor alpha (TNF-alpha) synthesis inhibitors based on an N-2,4-pyrimidine-N-phenyl-N'-phenyl urea scaffold is described. Many of these compounds showed low-nanomolar activity against lipopolysaccharide stimulated TNF-alpha production. X-ray co-crystallization studies with mutated p38alpha showed that these trisubstituted ureas interact with the ATP-binding pocket in a pseudo-bicyclic conformation brought about by the presence of an intramolecular hydrogen bonding interaction.
About this StructureAbout this Structure
2GHM is a Single protein structure of sequence from Mus musculus. Full crystallographic information is available from OCA.
ReferenceReference
Development of N-2,4-pyrimidine-N-phenyl-N'-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 1., Brugel TA, Maier JA, Clark MP, Sabat M, Golebiowski A, Bookland RG, Laufersweiler MJ, Laughlin SK, Vanrens JC, De B, Hsieh LC, Mekel MJ, Janusz MJ, Bioorg Med Chem Lett. 2006 Jul 1;16(13):3510-3. Epub 2006 May 2. PMID:16632356 Page seeded by OCA on Sun May 4 05:07:03 2008